記事

2007年11月23日

Organisation de la Presse Africaine

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Selon Oxfam International...l’industrie pharmaceutique empêche des millions de personnes pauvres d’avoir accès aux médicaments, mettant ainsi en péril son propre devenir...Sanofi-Aventis proposait son médicament ...Plavix à un prix 60 fois supérieur à ...[la] version générique indienne du médicament...Pfizer a ainsi intenté un procès au gouvernement des Philippines pour l’usage de clauses de sauvegarde invoquant la santé publique à l’égard du médicament Norvasc...

タイムライン

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2008年2月12日

コンテンツタイプ:

企業の回答

利用可能言語: English
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年12月19日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年12月18日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年12月18日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

日付:

2007年12月12日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年12月12日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年12月12日

コンテンツタイプ:

企業の回答

利用可能言語: English
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年12月12日

コンテンツタイプ:

企業の回答

利用可能言語: English
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年12月12日

コンテンツタイプ:

企業の回答

利用可能言語: English
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年12月12日

コンテンツタイプ:

企業の回答

利用可能言語: English
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年12月12日

コンテンツタイプ:

企業の回答

利用可能言語: English
Oxfam report "Investing for Life": Company responses

日付:

2007年12月12日

コンテンツタイプ:

記事

利用可能言語: English
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

日付:

2007年11月27日

コンテンツタイプ:

記事

利用可能言語: español
Oxfam says top drug companies focusing on patents, not poor

日付:

2007年11月26日

コンテンツタイプ:

記事

利用可能言語: English
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

日付:

2007年11月23日

コンテンツタイプ:

記事

利用可能言語: français
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

日付:

2007年11月12日

コンテンツタイプ:

企業の回答

利用可能言語: English
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices

日付:

2007年11月1日

コンテンツタイプ:

記事

利用可能言語: English

ストーリー全体を見る

さらに読み込む表示を減らす

Business & Human Rights
Resource Centre

月刊ニュースレター2024年3号

月刊ニュースレター2024年2月号

ビジネスと人権リソースセンター

月刊ニュースレター2024年3号

月刊ニュースレター2024年2月号

このページは日本語では利用できません。French で表示されています

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

タイムライン

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Oxfam report "Investing for Life": Company responses

La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Oxfam says top drug companies focusing on patents, not poor